REMS
Absorption: Rapidly and almost completely (80%) absorbed following oral administration.
Distribution: Varies with condition and patient; does not enter CSF well. Crosses the placenta and enters breast milk.
Protein Binding: >90% in patients with cerebral malaria, pregnant women, and children; 8590% in patients with uncomplicated malaria; 70% in healthy adults.
Half-Life: 11 hr (↑ in patients with malaria).
Contraindicated in:
Use Cautiously in:
CV: PR interval prolongation, QT interval prolongation, TORSADES DE POINTES
Derm: rash, STEVENS-JOHNSON SYNDROME
Endo: hypoglycemia
GI: abdominal cramps/pain, diarrhea, nausea, vomiting, hepatotoxicity
GU: ↓fertility (males)
Hemat: bleeding, blood dyscrasias, hemolytic anemia, HEMOLYTIC UREMIC SYNDROME, THROMBOCYTOPENIA, THROMBOTIC THROMBOCYTOPENIC PUPURA
Misc: cinchonism, HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS AND FEVER)
Drug-drug:
Renal Impairment
Lab Test Considerations:
Toxicity and Overdose: